Stanley Laman Group Ltd. decreased its position in shares of Danaher Co. (NYSE:DHR) by 0.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,011 shares of the conglomerate’s stock after selling 295 shares during the quarter. Danaher accounts for approximately 1.4% of Stanley Laman Group Ltd.’s investment portfolio, making the stock its 5th largest holding. Stanley Laman Group Ltd.’s holdings in Danaher were worth $6,004,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in DHR. Northern Trust Corp raised its position in Danaher by 0.4% during the first quarter. Northern Trust Corp now owns 8,887,690 shares of the conglomerate’s stock valued at $1,173,352,000 after acquiring an additional 34,065 shares in the last quarter. Geode Capital Management LLC raised its position in Danaher by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 7,527,142 shares of the conglomerate’s stock valued at $774,743,000 after acquiring an additional 583,194 shares in the last quarter. Findlay Park Partners LLP raised its position in Danaher by 0.9% during the first quarter. Findlay Park Partners LLP now owns 4,635,000 shares of the conglomerate’s stock valued at $611,913,000 after acquiring an additional 40,000 shares in the last quarter. Jennison Associates LLC purchased a new position in Danaher during the first quarter valued at approximately $489,930,000. Finally, American Century Companies Inc. raised its position in Danaher by 3.7% during the first quarter. American Century Companies Inc. now owns 3,700,569 shares of the conglomerate’s stock valued at $488,549,000 after acquiring an additional 133,300 shares in the last quarter. 79.35% of the stock is owned by hedge funds and other institutional investors.
Shares of Danaher stock traded down $3.11 on Wednesday, reaching $137.43. The company’s stock had a trading volume of 74,298 shares, compared to its average volume of 2,615,903. The firm has a market capitalization of $99.68 billion, a P/E ratio of 30.51, a P/E/G ratio of 2.53 and a beta of 0.94. Danaher Co. has a 52-week low of $94.59 and a 52-week high of $145.50. The business has a 50-day simple moving average of $141.56. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.32 and a quick ratio of 1.91.
Danaher (NYSE:DHR) last posted its quarterly earnings data on Thursday, July 18th. The conglomerate reported $1.19 EPS for the quarter, beating the Zacks’ consensus estimate of $1.15 by $0.04. The business had revenue of $5.16 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Danaher had a return on equity of 11.53% and a net margin of 12.22%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.15 earnings per share. Research analysts expect that Danaher Co. will post 4.79 earnings per share for the current year.
In related news, EVP William K. Daniel sold 164,164 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $132.43, for a total transaction of $21,740,238.52. Following the completion of the sale, the executive vice president now directly owns 194,627 shares in the company, valued at $25,774,453.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Robert S. Lutz sold 14,668 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $143.28, for a total value of $2,101,631.04. Following the sale, the chief accounting officer now owns 21,054 shares of the company’s stock, valued at $3,016,617.12. The disclosure for this sale can be found here. Insiders sold 392,121 shares of company stock valued at $53,603,339 over the last 90 days. Company insiders own 11.40% of the company’s stock.
Several brokerages recently weighed in on DHR. Royal Bank of Canada set a $134.00 price target on Danaher and gave the company a “hold” rating in a research report on Friday, July 19th. Wolfe Research began coverage on Danaher in a research report on Thursday, May 30th. They issued an “outperform” rating for the company. Piper Jaffray Companies boosted their price objective on Danaher from $148.00 to $153.00 and gave the company a “neutral” rating in a research report on Thursday, July 18th. Janney Montgomery Scott boosted their price objective on Danaher from $136.00 to $174.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Finally, Robert W. Baird boosted their price objective on Danaher from $131.00 to $148.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $143.54.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Article: Profit margin is different from the revenue
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.